# Kailera Therapeutics (KLRA) — Earnings

KLRA · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/klra/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$1.09 |
| EPS estimate | −$0.90 |
| EPS surprise | −21.42% |
| Revenue surprise | +0.00% |
| Revenue | $0.00 |
| Revenue estimate | $0.00 |
| Reported | Aug 12, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/2096997/000119312526346958/ck0002096997-20260630.htm) |

Kailera Therapeutics reported Q2 2026 results, for the quarter ended June 30, 2026, on August 12, 2026. It posted a loss of $1.09 per share, wider than the $0.90 loss expected, a 21.42% miss. No revenue was recorded for the quarter, and no revenue estimate was given.

The record is very short. This is the only quarter in the table, so there is no year-earlier quarter to compare with, no sequential trend and no annual total. There is also no history of beats or misses beyond this single result, which came in below the consensus. Any view of how the loss is developing, or of how results compare with expectations over time, will need more reports.

With only one report date on file, there is no established timing pattern yet. The Q2 report came about six weeks after the quarter ended. If Q3, which ends September 30, follows a similar gap, results would arrive around mid-November 2026. That report will give the first quarter-to-quarter comparison on this page, showing whether the loss per share widens or narrows from $1.09 and whether any revenue is recorded.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 12, 2026 | −$0.90 | −$1.09 | -21.42% | — | — |

## Frequently Asked Questions

### When did Kailera Therapeutics (KLRA) last report earnings?

Kailera Therapeutics last reported on Aug 12, 2026, covering fiscal Q2 2026.

### Did KLRA beat earnings estimates?

No. Kailera Therapeutics reported EPS of −$1.09 for Q2 2026 against a −$0.90 estimate — a 21.42% miss.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).